Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0684249 (
lung carcinoma
)
23,830
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Augmented antitumor activity in combination chemotherapy of
Nedaplatin
(
NDP
) or Cisplatin (CDDP) with Etoposide (ETP) against murine and human lung cancer cells was demonstrated.
NDP
and CDDP were administered once and ETP daily for five days via tail vein. In the mice bearing Lewis
lung carcinoma
, a combination of
NDP
and ETP resulted in synergistically enhanced inhibition of tumor growth, and prolonged survival in comparison with either
NDP
or ETP alone.
NDP
showed a more potent combination effect with ETP than CDDP did. These effects were also demonstrated in human lung cancer cell lines. Although body weight loss was enhanced by the combination of
NDP
or CDDP with ETP, it was tolerable, and no significant difference between
NDP
plus ETP and CDDP plus ETP was observed. Thrombocytopenia was not enhanced in the combined treatment of
NDP
with ETP. These results suggest the usefulness of the combination of
NDP
with ETP as a clinical therapy for lung cancer.
...
PMID:[Augmented antitumor activity in combination chemotherapy of nedaplatin with etoposide]. 946 33
Augmented antitumor activity was demonstrated in combination chemotherapy of
Nedaplatin
(
NDP
) or Cisplatin (CDDP) with 5-fluorouracil (5-FU) against murine
lung carcinoma
and human squamous carcinoma from head and neck. Either
NDP
or CDDP (1/4 to 1 maximum tolerated dose; MTD) was injected once and 5-FU (1/16 MTD) was injected daily for five days via tail vein to tumor-implanted mice. The sequential administration of either
NDP
or CDDP prior to 5-FU (NF or CF therapy) showed severe body weight loss followed by the toxic death of tumor-bearing mice at the MTD of
NDP
or CDDP. In contrast, the reverse sequence of the treatment, that is, 5-FU prior to
NDP
or CDDP (FN or FC therapy), resulted in the synergistically enhanced inhibition of tumor growth and the prolonged survival in comparison with
NDP
, CDDP or 5-FU monotherapy. The antitumor activities of the combinations of CDDP with 5-FU was less than those of the combination of
NDP
with 5-FU. Especially, at the MTD of
NDP
in FN therapy, long-term tumor-free survival was frequently observed. Thus, FN therapy was thought to be the most efficient regimen in combination of
NDP
with 5-FU as a clinical therapy.
...
PMID:[Augmented antitumor efficacy of combination chemotherapy of nedaplatin with 5-fluorouracil in in vivo murine and human tumor model]. 988 Oct 84
A 61-year-old man with cough and white sputum had an abnormal pulmonary mass in the left lower lobe in the computed tomography (CT) imaging. According to the lung cancer multidisciplinary team (MDT) discussion, the patient took the left lower lobe resection and lymphadenectomy and finally diagnosed as left lung adenocarcinoma with TNM stage IIIA (pT3N2M0). After four cycles of postoperative chemotherapy with pemetrexed and nedaplatin and 10-month release, a solitary pulmonary nodule (SPN) appeared in the middle lobe of right lung in CT scanning. The patient took a second operation "the right middle lobe resection" and was diagnosed as left lung adenocarcinoma at TNM stage IV (pT3N2M1a, two lungs) with neither EGFR mutation nor ALK-EML4 fusion gene. After operation, the patient took another four cycles of postoperative chemotherapy with Docetaxel and
Nedaplatin
. During the follow-up, another PET/CT scanning reported that several enlarged mediastinal lymph nodes, a SPN in left upper lobe and lesion in cerebellum and the brain metastasis was also proved in MRI. The patient was now diagnosed as left lung adenocarcinoma at TNM stage IV (pT3N2M1b, brain). In the third-line therapy, the patient took the stereotactic radiotherapy for metastatic mediastinal lymph nodes and took erlotinib once a day after the radiotherapy. However, the number of small lesions on lungs was increased and the brain metastasis was enlarged. The stereotactic radiotherapy for the single brain metastasis and single agent chemotherapy of abraxane were taken. The whole body examination suggested that there was progression-free after two cycles of chemo. The patient is now took five cycles of single agent chemotherapy of abraxane. The latest whole body examination showed disease was stable with no new lesions and metastasis, performance status (PS) score is 0 and the overall survival (OS) time is 34 months.
Transl
Lung Cancer
Res 2015 Feb
PMID:A 61-year-old man with cough and white sputum. 2580 49
